Cargando…

Letermovir for cytomegalovirus prophylaxis

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	NPS MedicineWise 2019
Materias:	New Drug
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594842/ https://www.ncbi.nlm.nih.gov/pubmed/31363312 http://dx.doi.org/10.18773/austprescr.2019.032

Ejemplares similares

2648. Terminating the Troll of Transplantation: Letermovir for Cytomegalovirus Prophylaxis
por: Hedvat, Jason, et al.
Publicado: (2019)

Tixagevimab and cilgavimab for COVID-19 prophylaxis
Publicado: (2022)

Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults
por: Politikos, Ioannis, et al.
Publicado: (2022)

Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience
por: Martino, Massimo, et al.
Publicado: (2021)

Letermovir for the compassionate therapeutic use of cytomegalovirus infection
por: Schubert, Lorenz, et al.
Publicado: (2020)

Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients
por: Körholz, Katharina F., et al.
Publicado: (2022)

Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient
por: Jung, Susanne, et al.
Publicado: (2019)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

928. Concordance with Institutional Guidelines for Letermovir Cytomegalovirus Infection Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Peterson-Weber, Alex, et al.
Publicado: (2023)

Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy
por: Restelli, Umberto, et al.
Publicado: (2019)

Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation
por: Daniels, Kori, et al.
Publicado: (2019)

In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication
por: Giménez, Estela, et al.
Publicado: (2023)

Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients
por: Royston, Léna, et al.
Publicado: (2021)

Letermovir Prophylaxis and Cytomegalovirus Reactivation in Adult Hematopoietic Cell Transplant Recipients with and without Acute Graft Versus Host Disease
por: Wolfe, Delaney, et al.
Publicado: (2021)

1995. Duration of letermovir primary prophylaxis in hematopoietic cell transplant recipients at high risk for cytomegalovirus infections and impact on outcomes
por: Febres-Aldana, Anthony J, et al.
Publicado: (2023)

Peramivir for influenza
Publicado: (2019)

Inotuzumab ozogamicin for acute lymphoblastic leukaemia
Publicado: (2019)

Guselkumab for plaque psoriasis
Publicado: (2019)

Durvalumab for urothelial carcinoma, non-small cell lung cancer
Publicado: (2019)

Cerliponase alfa for neuronal ceroid lipofuscinosis type 2 disease
Publicado: (2019)

Avanafil for erectile dysfunction
Publicado: (2019)

Telotristat ethyl for carcinoid syndrome diarrhoea
Publicado: (2019)

Tafenoquine succinate for malaria prevention
Publicado: (2019)

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019)

Plitidepsin for multiple myeloma
Publicado: (2019)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Binimetinib plus encorafenib for metastatic melanoma
Publicado: (2019)

Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Patiromer sorbitex calcium for hyperkalaemia
Publicado: (2019)

Tisagenlecleucel for B-cell cancers
Publicado: (2019)

Dupilumab for atopic dermatitis
Publicado: (2019)

Neratinib for breast cancer
Publicado: (2019)

Crisaborole for atopic dermatitis
Publicado: (2019)

MYOCRISIN
Publicado: (1941)

Brolucizumab for macular degeneration
Publicado: (2020)

Galcanezumab for migraine
Publicado: (2020)

Semaglutide for type 2 diabetes
Publicado: (2020)

Brigatinib for non-small cell lung cancer
Publicado: (2020)

Darolutamide for prostate cancer
Publicado: (2020)

Remdesivir for COVID-19
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j4bq9794e1futvrgqspuml4ane